Gynécologie - Ovaires GREAT 1550-C081 Genomic BRCA and Extensive ovArian cancer Testing Paris, Saint-Cloud MANUEL RODRIGUES, MANUEL RODRIGUES
Appareil Digestif REGIRI (PRODIGE 58) A randomised phase II trial assessing REGorafenib combined with IRInotecan as second-line treatment in patients with metastatic gastro-oesophageal adenocarcinomas Paris, Saint-Cloud
Gynécologie ROCSAN A multicentric randomized phase II/III evaluating TSR-042 (anti-PD-1 mAb) in combination with Niraparib (parpi) versus Niraparib alone compared to chemotherapy in the treatment of metastatic or recurrent endometrial or ovarian carcinosarcoma after at least one line of chemotherapy Paris
Appareil Digestif SAMCO (FFCD1603-PRODIGE 54) Multicenter Randomized Phase II Study Comparing the Effectiveness and Tolerance of Avelumab Versus Standard 2nd Line Treatment Chemotherapy in Patients With Colorectal Metastatic Cancer With Microsatellite Instability (MSI). Paris BRUNO BUECHER
Gynécologie - Ovaires TG4050.01 A phase I trial evaluating a mutanome-directed immunotherapy in patients with high grade serous carcinoma (HGSC) of the ovary, fallopian tube or peritoneum who experience an asymptomatic relapse Paris CHRISTOPHE LE TOURNEAU
Recherches "plusieurs pathologies" RAGNAR (42756493CAN2002) A Phase 2 Study of Erdafitinib in Subjects with Advanced Solid Tumors and FGFR Gene;Alterations Paris CHRISTOPHE LE TOURNEAU
Pédiatrie Tumeurs solides CA045-020 (PIVOT IO 020) Phase 1/2 Study of Bempegaldesleukin in Combination with Nivolumab in Children,;Adolescents, and Young Adults with Recurrent or Refractory Malignancies (PIVOT IO 020) Paris FRANCOIS DOZ
Gynécologie - Ovaires AGO-OVAR 2.29 Atezolizumab in combination with Bevacizumab and Chemotherapy;versus Bevacizumab and Chemotherapy;in recurrent ovarian cancer À a randomized Phase III trial;An ENGOT Trial Paris MANUEL RODRIGUES
Recherches "plusieurs pathologies" ALCINA 2 Analysis of Circulating Tumor Markers in Blood Paris, Saint-Cloud FRANCOIS-CLEMENT BIDARD, FRANCOIS-CLEMENT BIDARD
Recherches "plusieurs pathologies" ALCINA-4 (IC 2020-11) Analysis of Circulating Tumor mArkers in Blood 4 - ALCINA 4 Paris, Saint-Cloud FRANCOIS-CLEMENT BIDARD, FRANCOIS-CLEMENT BIDARD